The Management of Ascites and Hyponatremia in Cirrhosis

Pere Ginès; Andrés Cárdenas

doi:10.1055/s-2008-1040320

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2008; 28(1): 043-058
DOI: 10.1055/s-2008-1040320

The Management of Ascites and Hyponatremia in Cirrhosis

Pere Ginès¹ , Andrés Cárdenas²

¹Liver Unit, Hospital Clínic and University of Barcelona, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Ciber de Enfermedades Hepaticas y Digestivas (CIBERHED), Barcelona, Spain
²GI Unit, Hospital Clínic and University of Barcelona, Institut d'Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS), Ciber de Enfermedades Hepaticas y Digestivas (CIBERHED), Barcelona, Spain

Abstract

ABSTRACT

Ascites is the most common complication of cirrhosis and is associated with an increased risk for the development of infections, dilutional hyponatremia, renal failure, and mortality. Cirrhotic patients who develop ascites and associated complications have a low probability of long-term survival without liver transplantation, and therefore should be referred for evaluation of liver transplantation. While the initial management of uncomplicated ascites with low-sodium diet and diuretic treatment is straightforward in the majority of patients, there is a group of patients who fail to respond to diuretics and develop refractory ascites. The development of specific associated complications such as dilutional hyponatremia may further challenge the management of patients with ascites. New pharmacological agents such as the V2 receptor antagonists, drugs that directly antagonize the effects of elevated plasma antidiuretic hormone levels, induce solute-free water diuresis and seem to be promising in the management of patients with cirrhosis, ascites, and dilutional hyponatremia. This article focuses on the pathophysiology, clinical consequences, current management, and new treatment modalities for ascites and dilutional hyponatremia in cirrhosis.

KEYWORDS

Ascites - hyponatremia - vaptans

Volltext

Referenzen

REFERENCES

1 Minino A M, Heron M P, Smith B L. Deaths: preliminary data for 2004. Natl Vital Stat Rep. 2006; 54 1-49
2 Ginès P, Quintero E, Arroyo V et al.. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987; 7 122-128
3 Planas R, Montoliu S, Ballesté B et al.. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006; 4 1385-1394
4 Ginès A, Escorsell A, Ginès P et al.. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993; 105 229-236
5 Angeli P, Wong F, Watson H, Ginès P. CAPPS Investigators . Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006; 44 1535-1542
6 Ginès P. Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol. 2007; 46 1150-1152
7 Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988; 8 1151-1157
8 Iwakiri Y, Groszmann R. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43 S121-S131
9 Iwakiri Y, Groszmann R. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007; 46 927-934
10 Wiest R, Das S, Cadelina G et al.. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999; 104 1223-1233
11 Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005; 41 422-433
12 Riordan S M, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol. 2006; 45 744-757
13 Ruiz-del-Arbol L, Urman J, Fernández J et al.. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003; 38 1210-1218
14 Ruiz-del-Arbol L, Monescillo A, Arocena C et al.. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005; 42 439-447
15 Lee S S, Liu H. Cardiovascular determinants of survival in cirrhosis. Gut. 2007; 56 746-748
16 Sherlock S, Dooley J. Ascites. In: Sherlock S, Dooley J Diseases of the Liver and Biliary System. 11th ed. Oxford, England; Blackwell Science 2002: 127-146
17 Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350 1646-1654
18 Cárdenas A, Arroyo V. Ascites. In: Al-Knawy B, Sniffman M, Wiesner R Hepatology: A Practical Approach. Philadelphia; Elsevier Science 2005: 347-360
19 Moore K P, Wong F, Ginès P et al.. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003; 38 258-266
20 Runyon B A. Management of adult patients with ascites due to cirrhosis. Hepatology. 2004; 39 841-856
21 Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol. 2007; 21 77-93
22 Runyon B A, Antillon M R, Akriviadis E A, McHutchison J G. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol. 1990; 28 2811-2812
23 Ginès P, Berl T, Bernardi M et al.. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998; 28 851-864
24 Henkel A S, Buchman A L. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol.. 2006; 3 202-209
25 McCullough A J. Nutrition and malnutrition in liver disease. In: Wolfe MM, Davis GL, Farraye F, Giannella RA, Malagelada JR, Steer ML Therapy of Digestive Disorders. 2nd ed. Philadelphia; Saunders 2006: 67-83
26 Kearns P J, Young H, Garcia G et al.. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology. 1992; 102 200-205
27 Cabrè E, Gonzalez-Hux F, Abad-Lacruz A et al.. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics: a randomized controlled trial. Gastroenterology. 1990; 98 715-720
28 Perez-Ayuso R M, Arroyo V, Planas R et al.. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites: relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology. 1983; 84 961-968
29 Santos J, Planas R, Pardo A et al.. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis: a randomized comparative study of efficacy and safety. J Hepatol. 2003; 39 187-192
30 Li C P, Lee F Y, Hwang S J et al.. Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. Am J Gastroenterol. 2000; 95 1051-1055
31 Lee F Y, Lee S D, Tsai Y T et al.. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol. 1991; 12 236-240
32 Angeli P, Albino G, Carraro P et al.. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology. 1996; 23 264-273
33 Ginès P, Arroyo V, Quintero E et al.. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987; 93 234-241
34 Salerno F, Badalamenti S, Incerti P et al.. Repeated paracentesis and i.v. albumin infusion to treat “tense” ascites in cirrhotic patients. A safe alternative therapy. J Hepatol. 1987; 5 102-108
35 Moore K P, Aithal G P. Guidelines on the management of ascites in cirrhosis. Gut. 2006; 55(suppl 6) vi1-vi12
36 Ginès P, Tito L, Arroyo V et al.. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988; 94 1493-1502
37 Ruiz-del-Arbol L, Monescillo A, Jiménez W et al.. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997; 113 579-586
38 Ginès A, Fernández-Esparrach G, Monescillo A et al.. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996; 111 1002-1010
39 Moreau R, Valla D C, Durand-Zaleski I et al.. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver Int. 2006; 26 46-54
40 Sola-Vera J, Minana J, Ricart E et al.. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003; 37 1147-1153
41 Fernández-Esparrach G, Guevara M, Sort P et al.. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis: a randomized double-blind trial of spironolactone versus placebo. J Hepatol. 1997; 26 614-620
42 Thomsen T W, Shaffer R W, White B, Setnik G S. Videos in clinical medicine: paracentesis. N Engl J Med. 2006; 355 e21
43 Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005; 21 525-529
44 Caldwell S H, Hoffman M, Lisman T et al.. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006; 44 1039-1046
45 Cárdenas A, Guevara M, Ginès P. Paracentesis. In: Weinstein W, Hawkey CJ, Bosch J Clinical Gastroenterology and Hepatology. Philadelphia; Elsevier Science 2005: 1097-1100
46 Sakai H, Sheer T A, Mendler M H, Runyon B A. Choosing the location for non-image guided abdominal paracentesis. Liver Int. 2005; 25 984-986
47 Arroyo V, Ginès P, Gerbes A et al.. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996; 23 164-176
48 Guardiola J, Baliellas C, Xiol X et al.. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol. 2002; 97 2374-2378
49 Ginès P, Uriz J, Calahorra B et al.. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002; 123 1839-1847
50 Boyer T D, Haskal Z. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005; 41 386-400
51 Bureau C, García-Pagan J C, Otal P et al.. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004; 126 469-475
52 Lebrec D, Giuily N, Hadengue A et al.. Transjugular intrahepatic portosystemic shunts-comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol. 1996; 25 135-144
53 Rossle M, Ochs A, Gulberg V et al.. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000; 342 1701-1707
54 Sanyal A J, Genning C, Reddy R K et al.. The North American Study for Treatment of Refractory Ascites. Gastroenterology. 2003; 124 634-641
55 Salerno F, Merli M, Riggio O et al.. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004; 40 629-635
56 Allard J P, Chau J, Sandokji K, Blendis L M, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol. 2001; 96 2442-2447
57 Deltenre P, Mathurin P, Dharancy S et al.. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int. 2005; 25 349-356
58 Albillos A, Banares R, Gonzales M et al.. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol. 2005; 43 990-996
59 D'Amico G, Luca A, Morabito A et al.. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005; 129 1282-1293
60 Salerno F, Camma C, Enea M et al.. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007; 133 825-834
61 Cárdenas A, Ginès P. Management of refractory ascites. Clin Gastroenterol Hepatol. 2005; 3 1187-1191
62 Llach J, Ginès P, Arroyo V et al.. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988; 94 482-487
63 Guevara M, Cárdenas A, Uriz J, Ginès P. Prognosis of patients with ascites and cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier R Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Oxford; Blackwell Publishing 2005: 260-270
64 Kamath P S, Wiesner R H, Malinchoc M et al.. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33 464-470
65 Heuman D M, Abou-Assi S G, Habib A et al.. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004; 40 802-810
66 Biggins S W, Rodriguez H J, Bacchetti P, Bass N M, Robert J P, Terrault N A. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005; 41 32-39
67 Ruf A E, Kremers W K, Chavez L L, Descalzi V I, Podesta L G, Villamil F G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005; 11 336-343
68 Biggins S W, Kim W R, Terrault N A et al.. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130 1652-1660
69 Luca A, Angermayr B, Bertolini G et al.. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007; 13 1174-1180
70 Mathur S, Gane E J, McCall J L, Plank L D. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J Gastroenterol Hepatol. 2007; , April 19 (Epub ahead of print)
71 Londoño M C, Cardenas A, Guevara M et al.. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007; 56 1283-1290
72 Dawwas M F, Lewsey J D, Neuberger J M et al.. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007; 13 1115-1124
73 Londoño M C, Guevara M, Rimola A et al.. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006; 130 1135-1143
74 Fernández-Varo G, Ros J, Cejudo-Martin P et al.. Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003; 38 755-761
75 Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med. 2001; 138 18-21
76 Ginès P, Wong F, Watson H R et al.. Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), in patients with cirrhosis and ascites without hyponatremia. Hepatology. 2006; 44 691A
77 Wong F, Ginès P, Watson H R et al.. Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B), on recurrence of ascites after large volume paracentesis. Hepatology. 2006; 44 180A
78 Angeli P, Volpin R, Gerunda G et al.. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29 1690-1697
79 Ortega R, Ginès P, Uriz J et al.. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology. 2002; 36 941-948
80 Kalambokis G, Fotopoulos A, Economou M et al.. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol. 2007; 46 213-221
81 Lenaerts A, Codden T, Meunier J C et al.. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology. 2006; 44 844-849
82 Schrier R W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med. 2006; 119(suppl 1) S47-S53
83 Ishikawa S E, Schrier R W. Pathogenesis of hyponatremia: the role of arginine vasopressin in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis and Treatment. 2nd ed. Oxford; Blackwell Science 2005: 305-314
84 Thibonnier M, Conarty D M, Preston J A, Wilkins P L, Berti-Mattera L N, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998; 449 251-276
85 Kwon T H, Hager H, Nejsum L N, Andersen M L, Frokiaer J, Nielsen S. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001; 21 231-238
86 Nielsen S, Frokiaer J, Marples D, Kwon T H, Agre P, Knepper M A. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002; 82 205-244
87 Esteva-Font C, Baccaro M E, Fernández-Llama P et al.. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology. 2006; 44 1555-1556
88 Wong F, Blei A T, Blendis L M, Thuluvath P J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003; 37 182-191
89 Gerbes A L, Gülberg V, Ginès P et al.. The VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003; 124 933-939
90 Schrier R W, Gross P, Gheorghiade M et al.. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355 2099-2112
91 Ginès P, Wong F, Milutinovic D et al.. Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist on serum sodium concentration and ascites in patients with cirrhosis hyponatremia. J Hepatol. 2006; 44 732A
92 Ginès P, Wong F, Watson H. Long-term improvement of serum sodium by the V2-receptor antagonist satavaptan in patients with cirrhosis and hyponatremia. J Hepatol. 2007; 46 90A
93 Fraser C L, Arieff A I. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med. 1997; 102 67-77
94 Berl T, Verbalis J. Pathophysiology of water metabolism. In: Brenner & Rector's The Kidney. 7th ed. Philadelphia; Elsevier 2004: 857-920
95 Verbalis J G, Gullans S R. Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats. Brain Res. 1991; 567 274-282
96 Verbalis J G. The syndrome of inappropriate secretion of antidiuretic hormone secretion and other hyposmolar disorders. In: Schrier R Diseases of the Kidney and Urinary Tract. 8th ed. Philadelphia, PA; Lippincott Williams & Wilkins 2007: 2214
97 Halperin M L, Kamel K S. A new look at an old problem: therapy of chronic hyponatremia. Nat Clin Pract Nephrol.. 2007; 3 2-3
98 Haussinger D, Laubenberger J, vom Dahl S et al.. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994; 107 1475-1480
99 Häussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema. J Hepatol. 2000; 32 1035-1038
100 Haussinger D. Low-grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2006; 43 1187-1190
101 Laubenberger J, Haussinger D, Bayer S et al.. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology. 1997; 112 1610-1616
102 Minguez B, Garcia-Pagan J C, Bosch J et al.. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006; 43 707-714
103 Seery J P, Taylor-Robinson S D. The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. J Hepatol. 1996; 25 988-998
104 Butterworth R F. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002; 17 221-227
105 Butterworth R F. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol. 2003; 39 278-285
106 Restuccia T, Gómez-Ansón B, Guevara M et al.. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology. 2004; 39 1613-1622
107 Córdoba J, Gottstein J, Blei A T. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after porto-caval anastomosis. J Hepatol. 1998; 29 589-594
108 Shawcross D L, Balata S, Olde Damink S W et al.. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Gastrointest Liver Physiol. 2004; 287 G503-G509
109 Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride in intracranial pressure in patients with acute liver failure. Hepatology. 2004; 39 464-470
110 Baccaro M E, Guevara M, Torre A et al.. Hyponatremia predisposes to hepatic encephalopathy in patients with cirrhosis: results of a prospective study with time-dependent analysis. Hepatology. 2006; 44 118A
111 Guevara M, Uriz J, Arcos E et al.. Hyponatremia is a risk factor of hepatic encephalopathy in cirrhosis: a post hoc time-dependent analysis of the international study group on refractory ascites trial. Hepatology. 2006; 44 677A
112 Ginès P, Smajda Lew E, Diamand F. Hyponatremia is a major determinant of impaired health-related quality of life in cirrhosis with ascites. Hepatology. 2007; 46 744A
113 Abbasoglu O, Goldstein R M, Vodapally M S et al.. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant. 1998; 12 263-269
114 Wszolek Z K, McComb R D, Pfeiffer R F et al.. Pontine and extrapontine myelinolysis following liver transplantation: relationship to serum sodium. Transplantation. 1989; 48 1006-1012
115 Jalan R, Mookerjee R, Cheshire L et al.. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007; 46 232A
116 De Troyer A, Pilloy W, Broeckaert I, Demanet J C. Demeclocycline treatment of water retention in cirrhosis. Ann Intern Med. 1976; 85 336-337
117 Carrilho F, Bosch J, Arroyo V et al.. Renal failure associated with demeclocycline in cirrhosis. Ann Intern Med. 1977; 87 195-197
118 Decaux G, Mols P, Cauchie P et al.. Treatment of hyponatremic cirrhosis with ascites resistant to urea. Nephron. 1986; 44 337-343
119 Gadano A, Moreau R, Pessione F et al.. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol. 2000; 32 38-42
120 Inoue T, Ohnishi A, Matsuo A et al.. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther. 1998; 63 561-570
121 Thuluvath P J, Maheshwari A, Wong F et al.. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther. 2006; 24 973-982
122 Afdhal N, Cardenas A, Ginès P et al.. Randomized, placebo-controlled trial of tolvaptan, a novel V2-receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis. Hepatology. 2005; 42 LB19A

Pere GinèsM.D.

Liver Unit, Hospital Clínic, Villarroel 170

08036 Barcelona, Spain

eMail: pgines@clinic.ub.es